Quarterly ResultMay 7, 2026, 09:37 AM
Aardvark Therapeutics Q1 Net Loss Widens to $21.6M
AI Summary
Aardvark Therapeutics reported a significant increase in net loss for Q1 2026, reaching $21.6 million, up from $9.3 million in Q1 2025, primarily due to higher research and development and general and administrative expenses. The company's cash, cash equivalents, and short-term investments totaled $91.2 million as of March 31, 2026, which is expected to sustain operations for at least one year. In March 2026, Aardvark established an ATM facility to potentially raise up to $150.0 million.
Key Highlights
- Net loss for Q1 2026 increased to $21.6 million from $9.3 million in Q1 2025.
- Research and development expenses rose 113.6% to $16.6 million in Q1 2026.
- General and administrative expenses increased 117.2% to $5.9 million in Q1 2026.
- Cash, cash equivalents, and short-term investments totaled $91.2 million as of March 31, 2026.
- Net cash used in operating activities was $18.9 million for Q1 2026.
- Established an ATM facility in March 2026 to sell up to $150.0 million in common stock.
- Accumulated deficit reached $137.5 million as of March 31, 2026.
Price Impact
More from AARD